Hennion & Walsh Asset Management Inc. Raises Stake in Jazz Pharmaceuticals PLC $JAZZ

Hennion & Walsh Asset Management Inc. raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 25.5% during the fourth quarter, HoldingsChannel reports. The firm owned 47,535 shares of the specialty pharmaceutical company’s stock after buying an additional 9,657 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Jazz Pharmaceuticals were worth $8,081,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in JAZZ. Dimensional Fund Advisors LP boosted its stake in shares of Jazz Pharmaceuticals by 11.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after buying an additional 298,815 shares during the period. Capital World Investors increased its position in Jazz Pharmaceuticals by 0.4% in the 3rd quarter. Capital World Investors now owns 2,554,867 shares of the specialty pharmaceutical company’s stock valued at $336,731,000 after acquiring an additional 10,345 shares during the period. Ameriprise Financial Inc. increased its position in Jazz Pharmaceuticals by 11.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after acquiring an additional 191,637 shares during the period. JPMorgan Chase & Co. raised its stake in Jazz Pharmaceuticals by 8.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after acquiring an additional 145,865 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $127,344,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Friday. Wells Fargo & Company upped their price target on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Bank of America lifted their price objective on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Finally, Barclays reissued an “overweight” rating and issued a $224.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $215.38.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,287 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $182.94, for a total value of $235,443.78. Following the completion of the sale, the chief accounting officer owned 6,512 shares of the company’s stock, valued at approximately $1,191,305.28. This trade represents a 16.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Norbert G. Riedel sold 3,415 shares of the business’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $192.00, for a total transaction of $655,680.00. Following the sale, the director owned 7,024 shares in the company, valued at $1,348,608. The trade was a 32.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 68,015 shares of company stock worth $13,037,486. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $182.69 on Monday. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. The stock’s 50 day moving average is $175.63 and its two-hundred day moving average is $160.29. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $198.00. The firm has a market capitalization of $11.25 billion, a PE ratio of -30.60, a P/E/G ratio of 0.33 and a beta of 0.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the business posted $6.51 EPS. The company’s revenue for the quarter was up 8.1% on a year-over-year basis. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.